Company
Oxford BioMedica PLC
LON:OXB
Oxford BioMedica is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how.
69 stories
AstraZeneca secures Covid-19 vaccine production amid safety concerns
The two companies first struck a supply and development deal for the vaccine in September 2020
UK Covid-19 cases jump by a third in a single week
The latest cases are thought to be caused by the Omicron variant
Oxford Biomedica, Smith & Nephew 'vulnerable' to takeover
RBC anticipates more takeovers in the healthcare space after a flurry of recent bids for mid-cap listed assets
Oxford Biomedica in deal with Homology to set up new AAV manufacturing and innovation business
The company also said it will raise £80mln in a placing
Oxford Biomedica inks licence and supply deal for LentiVector with Cabaletta Bio
US-based Cabaletta Bio develops engineered T cells designed to treat patients with autoimmune diseases
Oxford Biomedica doubles financial guidance after AstraZeneca increases COVID-19 vaccine production
The group is a key manufacturer of what is known as the Oxford/AstraZeneca jab
Oxford Biomedica 'buy' recommendation reiterated as COVID-19 vaccine manufacturer's revenues soar
With revenues rolling in from the COVID-19 vaccine the group is expecting another year of strong top-line growth.
Oxford Biomedica clinches CAR-T cell therapies collaboration with PhoreMost
The programme aims to develop next-generation cell therapies with improved efficacy and durability
Oxford Biomedica receives approval for COVID-19 vaccine candidate manufacturing site
The approval completes a phase of expansion that more than doubles the group's manufacturing capacity compared to 2019
Oxford Biomedica, AstraZeneca sign agreement to produce COVID-19 vaccine candidate
Oxford Biomedica will receive £15mln upfront as a capacity reservation fee, plus additional revenue in excess of £35mln
Oxford Biomedica secures third partnership in CAR-T field
NASDAQ-listed Beam Therapeutics signed up to use the firm's LentiVector platform in its projects
The four coronavirus vaccine candidates to watch
Oxford University, Moderna, Johnson & Johnson and a partnership between Pfizer and BioNTech are developing the lead candidates, according to experts
Archive
Oakley Capital Investments bounces as it nets £99mln from sale of Inspired stake
A look at some of the major risers and fallers in London on Wednesday
Oxford Biomedica shares jump as Novo Holdings pays £53.5mln for 10% stake in the firm
Oxford said the proceeds of the investment will be used to repay debt and develop its products
Investments and investor services
Tertiary Minerals higher after announcing a new project acquisition in Nevada
A look at the day's major movers, including Pressure Technologies. Clontarf Technologies, Oxford Biomedica, Trafalgar Property, Yü, Proton Power and Frontier IP
Archive
FTSE 100 closes higher as no deal Brexit fears ease
Footsie closed around 26 points higher at 7,185, while FTSE 250 added around 103 points at 19,283
Archive
Thursday's Brexit fallout likely to overshadow Capita and Savills results
Brexit and the latest vote will likely be the main talking point, but there will be financial results too!
Two huge licensing deals help Oxford BioMedica swing to a first-half profit
Oxford signed deals with Bioverativ and Axovant, which could be worth upwards of US$1bn over the next few years
FTSE 100 finishes lower as BoE keeps rates on hold; sterling gains
The UK benchmark index of leading shares finished down nearly 32 points at 7,281
Investments and investor services
Morrisons in the spotlight as discounters are seeing a slowdown
The supermarket is the likely standouts in Thursday's market diary.
Archive
Heatwave may help or hurt sales at Wetherspoons, JD Sports, Primark and Dunelm
The week ahead includes annual results from Wetherspoons, Galliford Try and Dunelm along with interims from Morrisons and trading updates from AB Foods and Ashtead
CAR-T therapies: All you wanted to know and were too afraid to ask
Immuno-oncology has become a popular field of research with UK companies at the forefront of the latest innovations
Gene therapy deal to drive “pipeline transformation” for Axovant Sciences, says Oppenheimer
Axovant expects to initiate a study of AXO-Lenti-PD in patients with advanced Parkinson's disease by the end of 2018
PowerHouse Energy shares lifted as it debunks speculation on Science Park closure
A look at some of the biggest risers and fallers in London on Wednesday
Oxford BioMedica shares jump as it enters licensing agreement for Parkinson’s treatment
The gene and cell therapy group said under the agreement with Axovant Sciences it would receive a US$30mln upfront payment
Archive
Momentum investing: Use the Force, Luke
A lot of academic research suggests a momentum investing strategy outperforms the market. John Harrington attempts to concoct a lazy person's momentum investing system.
Oxford BioMedica’s shares shares rise after unveiling US$100mln agreement with Bioverativ
Oxford BioMedica will receive a US$5mln payment upfront and will be eligible to receive various milestone payments potentially worth in excess of US$100mln
FTSE 100 closes in the red but gold price boosts miners
The FTSE 100 closed down 45 at 7,387, while the FTSE 250 lost 86 at 19,773.
What’s in store for Kingfisher investors on Thursday?
The B&Q owner's French business has overshadowed recent decent performances, will it blight the next figures?
Archive
UK economic health eyed from inflation, jobless numbers; Kingfisher updates on trading
Week ahead includes UK inflation, unemployment, average earnings data; trading update from Kingflsher PLC, interims from Hargreaves Lansdown PLC, Admiral PLC ...
Oxford Biomedica extends contract with Swiss pharma giant Novartis
Oxford Biomedica said a new contract with Novartis could generate more than US$100mln over the next three years
Archive
Fed fall-out, Dutch elections and Sainsbury's sales to provide food for thought
A rise is taken as read, and – assuming the Fed does not perform a triple Salchow with accompanying back-flip – the focus will be on the Fed’s commentary in its post-meeting statement.
Oxford Biomedica lauds “encouraging” trial results from a Phase I/II cancer trial involving its TroVax immunotherapy product
The firm said the results showed patients given TroVax and low dose cyclophosphamide demonstrated “significant anti-5T4 immune responses”
Risers and fallers: Nyota, Conroy Gold, Centamin, Ascent Resources, Shanta Gold, Legendary Investments
Main share price risers and fallers in London at 3.45pm
PREVIEW; GameAccount Network needs more landmark deals
Other companies reporting include Lloyds Banking, Taylor Wimpey and WPP
FTSE 100 hits new high for 2016 after late surge
The Footsie put on a late spurt to finish in the blue, as US stocks roused themselves after a sluggish start.
London shares fall as Kuwaiti oil workers end strike
Shares dropped as crude prices fell, but Stagecoach provided interest
Market gains silver lining as precious metals twinkle
Silver prices hit a 10-month high and gold stocks glittered
Sainsbury interest in Home Retail buoys London shares
Sainsbury's approached Home Retail in November about cash-and-share deal
Investments and investor services
Top flight rises but Next disappoints
The FTSE 100 Index climbed 34 points to 6127 following yesterday's 150-point drop
Investments and investor services
Risers & Fallers: Corero Network, Home Retail, Egdon Resources, Greka Drilling...
Below are the main news-driven share price movements at 4pm.
Investments and investor services
FTSE 100 gets afternoon boost from Glaxo
Stocks were on an upward trend, helped by a recovery by commodity plays
London's shares remain slightly higher at lunch
GlaxoSmithKline, BT and British American Tobacco led the way higher
Investments and investor services
Risers & Fallers: Opsec Security, PeerTV, Plexus, Plutus Powergen, DJI Holdings and more...
Below are the main news-driven share price movements at 4pm.
Risers & Fallers: Xaar, Aldermore, Standard Chartered, HSS Hire, OneSavings and more...
Below are the main news-driven share price movements at 4pm.
London shares rise as US and Chinese markets rebound
Chinese markets rose "as state-directed investors bought shares"
Thursday's agenda: Oil and the Fed to take centre stage
Oil service providers Amec Foster Wheeler, Lamprell and Hunting, are scheduled to update the market on Thursday.
Cancer drug firms to cash in on $9bn immunotherapy market
Trials have shown that immunotherapy may revolutionise cancer treatment